Paula Curtis

1.9k total citations · 1 hit paper
25 papers, 1.4k citations indexed

About

Paula Curtis is a scholar working on Rheumatology, Radiology, Nuclear Medicine and Imaging and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Paula Curtis has authored 25 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Rheumatology, 8 papers in Radiology, Nuclear Medicine and Imaging and 7 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Paula Curtis's work include Systemic Lupus Erythematosus Research (10 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Diabetes Treatment and Management (5 papers). Paula Curtis is often cited by papers focused on Systemic Lupus Erythematosus Research (10 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Diabetes Treatment and Management (5 papers). Paula Curtis collaborates with scholars based in United Kingdom, United States and Spain. Paula Curtis's co-authors include Nigel C. Jones, Philip Home, Ramón Gomis, Stuart Pocock, Henning Beck‐Nielsen, M Hanefeld, Michel Komajda, John J.V. McMurray, David A. Roth and B. McQuade and has published in prestigious journals such as The Lancet, SHILAP Revista de lepidopterología and Diabetes Care.

In The Last Decade

Paula Curtis

22 papers receiving 1.3k citations

Hit Papers

Rosiglitazone evaluated for cardiovascular outcomes in or... 2009 2026 2014 2020 2009 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
    2009 1.0k citations Philip Home, Stuart Pocock et al. The Lancet profile →

Peers

Paula Curtis
Mario N. Piccinni Italy
Gary Ko Hong Kong
Michele T. Rooney United States
Kengo Azushima Japan
Hiromichi Wakui Japan
Sidney Rosenblatt United States
Zhen-Yan Fu China
Mehmood Khan United States
Stefan Schäfer Germany
Niels Jongs Netherlands
Mario N. Piccinni Italy
Paula Curtis
Citations per year, relative to Paula Curtis Paula Curtis (= 1×) peers Mario N. Piccinni

Countries citing papers authored by Paula Curtis

Since Specialization
Citations

This map shows the geographic impact of Paula Curtis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paula Curtis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paula Curtis more than expected).

Fields of papers citing papers by Paula Curtis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paula Curtis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paula Curtis. The network helps show where Paula Curtis may publish in the future.

Co-authorship network of co-authors of Paula Curtis

This figure shows the co-authorship network connecting the top 25 collaborators of Paula Curtis. A scholar is included among the top collaborators of Paula Curtis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paula Curtis. Paula Curtis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Weinblatt, Michael E., Peter C. Taylor, Iain B. McInnes, et al.. (2025). Long-term safety and efficacy of anti-GM-CSF otilimab in patients with rheumatoid arthritis: long-term extension of three phase 3 randomised trials (contRAst X). BMJ Open. 15(3). e088869–e088869. 1 indexed citations
2.
Furie, Richard, Hans‐Joachim Anders, George Βertsias, et al.. (2025). COMPLETE RENAL RESPONSES AND SAFETY FOR BELIMUMAB VERSUS PLACEBO IN A POST HOC MYCOPHENOLATE MOFETIL SUBGROUP WITH ACTIVE PROLIFERATIVE LUPUS NEPHRITIS. The Journal of Rheumatology. 52(Suppl 1). 50–51.
3.
Curtis, Paula, Munther A. Khamashta, Ricard Cervera, et al.. (2024). 1501 Long-term safety of belimumab among adult patients with systemic lupus erythematosus (SLE): pooled data from three open-label extension studies over 11+ years. SHILAP Revista de lepidopterología. A113.2–A114.
4.
Mian, Asad, Paula Curtis, M A Khamashta, et al.. (2023). AB0519 LONG-TERM SAFETY OF BELIMUMAB AMONG ADULT PATIENTS WITH SLE: POOLED DATA FROM THREE OPEN-LABEL EXTENSION STUDIES OVER 11+ YEARS. Annals of the Rheumatic Diseases. 82. 1454–1455.
5.
Bae, Sang‐Cheol, Damon Bass, Myron Chu, et al.. (2022). The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week study. Arthritis Research & Therapy. 24(1). 46–46. 8 indexed citations
6.
Furie, Richard, Brad H. Rovin, Frédéric Houssiau, et al.. (2022). Safety and Efficacy of Belimumab in Patients with Lupus Nephritis. Clinical Journal of the American Society of Nephrology. 17(11). 1620–1630. 38 indexed citations
7.
Tanaka, Yoshiya, Sang‐Cheol Bae, Damon Bass, et al.. (2021). Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea. RMD Open. 7(2). e001629–e001629. 18 indexed citations
8.
Tanaka, Yoshiya, Paula Curtis, Regina Kurrasch, et al.. (2021). Long-term safety and efficacy of belimumab in Japanese patients with SLE: A 7-year open-label continuation study. Modern Rheumatology. 33(1). 122–133. 5 indexed citations
9.
Rovin, Brad H., Richard Furie, Frédéric Houssiau, et al.. (2021). FC 034SAFETY AND EFFICACY OF INTRAVENOUS BELIMUMAB IN PATIENTS WITH LUPUS NEPHRITIS: A 6-MONTH OPEN-LABEL EXTENSION. Nephrology Dialysis Transplantation. 36(Supplement_1). 1 indexed citations
10.
Subías, Pilar Escribano, et al.. (2019). Ambrisentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH). Pulmonary Circulation. 9(2). 1–3. 24 indexed citations
11.
Jones, Nigel C., Paula Curtis, & Philip Home. (2014). Cancer and bone fractures in observational follow-up of the RECORD study. Acta Diabetologica. 52(3). 539–546. 10 indexed citations
12.
MacDonald, Michael R., Mark C. Petrie, Philip Home, et al.. (2011). Incidence and Prevalence of Unrecognized Myocardial Infarction in People With Diabetes. Diabetes Care. 34(6). 1394–1396. 25 indexed citations
13.
Home, Philip, Stuart Pocock, Henning Beck‐Nielsen, et al.. (2009). Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. The Lancet. 373(9681). 2125–2135. 1006 indexed citations breakdown →
14.
15.
Crisp, Adam & Paula Curtis. (2007). Sample size estimation for non‐inferiority trials of time‐to‐event data. Pharmaceutical Statistics. 7(4). 236–244. 11 indexed citations
16.
Home, Philip, Nigel C. Jones, Stuart Pocock, et al.. (2007). Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabetic Medicine. 24(6). 626–634. 66 indexed citations
17.
Beck‐Nielsen, Henning, M Hanefeld, Michel Komajda, et al.. (2005). Randomized controlled trial of the effect of rosiglitazone in combination therapy on ambulatory blood pressure in people with type 2 diabetes mellitus followed for 12 months. 3 indexed citations
18.
19.
Davidson, Neville, Bernardo L. Rapoport, Björn Erikstein, et al.. (1999). Comparison of an orally disintegrating ondansetron tablet with the conventional ondansetron tablet for cyclophosphamide-induced emesis in cancer patients: A multicenter, double-masked study. Clinical Therapeutics. 21(3). 492–502. 25 indexed citations
20.
Curtis, Paula, et al.. (1999). Customer-focused design data in a large, multi-site organization. 608–615. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mario N. Piccinni Breakdown of academic impact, for papers by Gary Ko Breakdown of academic impact, for papers by Michele T. Rooney Breakdown of academic impact, for papers by Kengo Azushima Breakdown of academic impact, for papers by Hiromichi Wakui Breakdown of academic impact, for papers by Sidney Rosenblatt Breakdown of academic impact, for papers by Zhen-Yan Fu Breakdown of academic impact, for papers by Mehmood Khan Breakdown of academic impact, for papers by Stefan Schäfer Breakdown of academic impact, for papers by Niels Jongs
Rankless by CCL
2026